Variables | All-Patients (n = 37) | Responders (n = 23) | Non-Responders (n = 14) | P-valuea |
---|---|---|---|---|
Demographic data | ||||
 Age (years) | 83 (79–87) | 82 (79.5–86.5) | 84 (79–88) | 0.754 |
 Gender (Men) | 21 (57%) | 13 (57%) | 8 (57%) |  > 0.999 |
Severity scores | ||||
 APACHE II | 27 (25–32) | 27 (26–32) | 27 (22.8–32) | 0.975 |
 SOFA score, day-1 | 11 (8–13) | 11 (9–13.5) | 11.5 (8–13) | 0.801 |
 SOFA score, day-3 | 9 (7–12) | 8 (6–11.5) | 9.5 (8.3–13) | 0.127 |
 SOFA score, day-7 | 7 (5–9) | 5 (4–7.5) | 9 (7–12)b | 0.017 |
Comorbidities | ||||
 Diabetes mellitus | 7 (19%) | 4 (17%) | 3 (21%) |  > 0.999 |
 Congestive heart failure | 7 (19%) | 5 (22%) | 1 (7%) | 0.687 |
 COPD | 4 (11%) | 4 (17%) | 0 (0%) | 0.276 |
 End-stage renal disease | 9 (24%) | 6 (26%) | 3 (21%) |  > 0.999 |
 Cerebral vascular disease | 7 (19%) | 5 (22%) | 2 (14%) | 0.687 |
Laboratory data | ||||
 White blood cell count (/ml) | 11,760 (8670–14,160) | 12,720 (11,120–14,155) | 10,680 (7455–13,615) | 0.199 |
 High Platelet count (1000/ml) | 253 (148–355) | 289 (197.5–367.5) | 202.5 (120.8–312.8) | 0.294 |
 Low Platelet count (1000/ml) | 75 (27–122) | 80 (33.5–149) | 44.5 (23.5–111.3) | 0.260 |
 Lactate(mg/dl) | 32.7 (21.3–60.2) | 32.7 (21.4–61.3) | 33.8 (19.5–51.1) |  > 0.999 |
 Albumin(mg/dl) | 3.3 (3–3.7) | 3.3 (3.2–3.7) | 3 (2.7–3.5)b | 0.016 |
 C-reactive protein(mg/dl) | 9.16 (3.9–17.5) | 5.92 (3.1–14.0) | 15.74 (9.6–21.7)b | 0.015 |
Outcome | ||||
 Ventilator-days | 16 (8–23) | 10 (6.5–16.5) | 21 (19–28)b | 0.040 |
 ICU length of stay, days | 17 (12–23) | 13 (9.5–18.5) | 23 (19–30.5)b | 0.037 |
 Hospital length of stay, days | 32 (26–51) | 29 (25–48.5) | 43 (29–66.3) | 0.471 |
 Mortality | 8 (22%) | 1 (4%) | 7 (50%)b | 0.002 |